HAIMOVITCH MEDICAL

TECHNOLOGY CONSULTANTS

 
 

Meeting focuses on capital investment for med-tech


By Larry Haimovitch

Medical Device Daily Contributing Writer

June 27, 2012

SAN FRANCISCO — The 20th annual Medical Device Conference, sponsored by the law firm of Wilson Sonsini Goodrich & Rosati (WSG&R; Palo Alto, California) was held here at the historic Sheraton Palace Hotel in downtown San Francisco.

This meeting, the "granddaddy" of venture capital (VC) oriented gatherings, draws from a variety of groups, including VCs, medical device entrepreneurs, patent attorneys, accounting firms and other service providers to the medical device industry. As usual, attendance was robust, with more than 600 attendees.

Whereas last year's meeting focused heavily on the "F" word (the FDA) this year's meeting delved deeply into how medical device companies could raise money in a very challenging money raising environment.

The first session, titled "Venture Strategies," featured several venture capitalists who engaged in a lively discussion with moderator Marty Waters of WSG&R. Responding to the question "Why has VC med-tech investing declined so sharply in the past few years?," Mike Carusi, a general partner at Advanced Technology Ventures (Palo Alto, California) responded by saying simply: "VCs have less money to invest now than in the past."

Carusi pointed out that in five of the past six years "VCs have invested more money than was invested by their limited partners." In essence, the inflow of funds has declined so much so that VCs are unable to keep pace with historical investing norms.

He kiddingly blamed the VC's limited partners, who he called "the villains."

Yuval Binur, managing partner of Orchestra Medical Ventures (New York City) flatly stated that "the VC investing model, which was developed many years ago, is broken."

He went on to opine "there is no shortage of innovation, the issue is simply that there is a lack of available funding."

His firm's approach is neatly summarized on its website: "Orchestra immerses itself into selected high-value, high-need clinical sectors in order to identify and analyze important unmet clinical needs that provide significant opportunities for technology innovations that can improve outcomes while reducing costs and complications."

Binur emphasized that it is crucial to identify unmet clinical needs, and then develop credible clinical data. He fervently stressed the latter point, saying "it's all about the clinical data." He further commented that entrepreneurs and investors should seek to solve "fundamental needs and avoid 'me-too-ism.'"

Regarding good clinical data, Binur noted that it does not mean that FDA approval has to be secured but that "Level 1" clinical data must be developed.

Bill Harrington, formerly a partner at Three Arch Partners (Portola Valley, California), joined Osage University Partners (Bala Cynwyd, Pennsylvania) in early 2012 and explained that his new firm's philosophy is well-suited for today's environment, as it can gain access to early stage med-tech opportunities through its relationships with universities.

As noted on its website, Osage's "unique model, through which it manages the co-investment rights held by its affiliated universities . . . (allows it). . contractual access to invest in the future financings of some of the most promising startup companies that have licensed technology from those universities."

An additional key point that was consistently expressed by the panelists was "be cautious about your commercialization efforts and investments." John Friedman, managing partner and founder of Easton Capital Investment Group (New York), proposed the idea of "dominate locally" when your company introduces a new product. That is, do not hire a nationwide sales and marketing team, which is very costly and also risky but rather focus on creating success in a small market area. A potential acquirer or strategic partner can easily extrapolate that narrow market success into a successful national sales effort.

Friedman's sentiments were strongly supported by Binur, who said "early stage companies are not skilled in commercialization and therefore should not do this" Rather, he again lobbied for gathering convincing clinical data.

Another interesting panel, titled "M & A, IPOs and Strategic Partnerships," delved into how to deal with the very challenging times in fund raising.

Rich Ferrari, a co-founder of the VC firm De Novo Ventures (Menlo Park, California) wistfully recalled the "insanely robust" IPO market in the mid-1990s. Ferrari was CEO of Cardiothoracic Systems, a minimally invasive cardiac surgery company that went public in 1996 with a market value of $300 million. At the time of its public debut, it had virtually no revenue.

There were two med-tech IPOs in 2011 and none so far this year. One of the two 2011 IPOs, Zeltiq Aesthetics (Pleasanton, California; Medical Device Daily, Oct. 11, 2011), was described recently "as one of the most disappointing IPOs of 2011 for all industries," having plunged about 70% from its IPO price.

With the IPO window virtually shut and VC funding sharply lower, Ferrari's prescription for financing was "angels, friends, families and grants."

Amir Belson, a highly successful med-tech entrepreneur, presented his thoughts and concurred with Ferrari. His latest startup, Zipline Medical (Campbell, California), has been financed with minimal venture capital funding but has relied mainly on small investor and friends.

One of the most successful VCs in recent years has been Ned Scheetz, the founder and managing director of Aphelion Capital (Mill Valley, California). Since its founding in 2005, Aphelion has closely adhered to a model of supporting the growth of innovative medical technology with an emphasis on fast to market, low capital intense products that also can reduce the cost of delivering quality healthcare.

Aphelion does not invest in companies that require an FDA pre-market approval (PMA) and has invested mainly in very early stage companies, which require a modest amount of capital to reach commercialization.

Scheetz cited the example of Orthoscan (Scottsdale, Arizona), which was acquired by ATON (Halbergmoos, Germany) in September 2011 as a model of his investing style. Aphelion originally invested in Orthoscan in September 2007, joined the board and helped to re-structure the management team. On a modest amount of capital, Orthoscan successfully launched a mini C-arm for orthopedic imaging and annual sales ramped quickly to about $25 million.

ATON, a large German conglomerate with annual global sales of more than $2 billion, was attracted by Orthoscan's innovative technology, which affords significantly better diagnostic accuracy. Although the purchase price was not publicly disclosed, Aphelion's rate of return was outstanding.

Scheetz said that a key point in considering an investment opportunity "is there a clear path to the market."

He also commented that he expects merger and acquisition activity from the larger, slower growing med-tech companies to continue and perhaps even accelerate as these companies are flush with cash and seek innovative, more rapidly growing companies to add to their portfolios.

2012 Wilson Sonsini Conference

contact.html
about.html
articles.html
Services.html
index.html
Homeindex.htmlindex.htmlshapeimage_6_link_0
ServicesServices.htmlServices.htmlshapeimage_7_link_0
Articlesarticles.htmlarticles.htmlshapeimage_8_link_0
About HMTCabout.htmlabout.htmlshapeimage_9_link_0
Contactcontact.htmlcontact.htmlshapeimage_10_link_0